Katharine H. Dixon

A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells.

Katharine H. Dixon, Brendan C. Lanpher, Jason Chiu et al. · Journal of Biological Chemistry · 1994 · 242 citations · Full text

Metabolic Remodeling, Cancer Biology, Cellular Physiology +16

HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.

R. Todd Reilly, Morris B.C. Gottlieb, Anne M. Ercolini et al. · PubMed · 2000 · 216 citations

Knockout Mouse, Radiation Oncology, Cancer Immunosurveillance +15

Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells.

Jeffrey A. Moscow, Maokaı̈ Gong, Rui He et al. · PubMed · 1995 · 202 citations

Tumor Biology, Breast Oncology, Tumor Heterogeneity +15

Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells.

Masayuki Nakagawa, E Schneider, Katharine H. Dixon et al. · PubMed · 1992 · 137 citations

Tumor Biology, Breast Oncology, Oncology +13

Stable transfectants of human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates.

Kyung‐Hwun Chung, Yutaka Saikawa, Tae-Hyun Paik et al. · Journal of Clinical Investigation · 1993 · 77 citations · Full text

Hfr Grow, Breast Oncology, Stable Transfectants +15